These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 340258)
1. [Interaction of L-DOPA and pyridoxine (a review of the literature)]. Uspenskiĭ AE Farmakol Toksikol; 1977; 40(6):722-33. PubMed ID: 340258 [No Abstract] [Full Text] [Related]
2. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose. Granerus AK; Jagenburg R; Rödjer S; Svanborg A Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974 [No Abstract] [Full Text] [Related]
3. [Facilitation of the effects of L-DOPA by alpha-methyldopa]. Uspenskiĭ AE; Korobov NV Biull Eksp Biol Med; 1976 Mar; 81(3):314-6. PubMed ID: 986203 [TBL] [Abstract][Full Text] [Related]
4. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Kostrzewa RM; Kostrzewa JP; Brus R Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519 [TBL] [Abstract][Full Text] [Related]
5. [Alphamethyldopa and levodopa interaction]. Sjönell G Lakartidningen; 1979 Nov; 76(45):4008. PubMed ID: 522553 [No Abstract] [Full Text] [Related]
7. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)]. Hanzal F MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of L-dopa in patients with Parkinson's disease. Mena MA; Muradas V; Bazan E; Reiriz J; de Yebenes JG Adv Neurol; 1987; 45():481-6. PubMed ID: 2950730 [No Abstract] [Full Text] [Related]
9. Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake. Andersson I; Granerus AK; Jagenburg R; Svanborg A Acta Med Scand; 1975 Nov; 198(5):415-20. PubMed ID: 1199816 [TBL] [Abstract][Full Text] [Related]
10. Levadopa and pyridoxine. Mars H; Barrera ER; Bennett S JAMA; 1972 Mar; 219(13):1764. PubMed ID: 5067250 [No Abstract] [Full Text] [Related]
11. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Hornykiewicz O Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520 [TBL] [Abstract][Full Text] [Related]
12. The effect of L-DOPA on brain polysomes and protein synthesis: probable mediation by intracellular dopamine. Weiss BF; Roel LE; Munro HN; Wurtman RJ Adv Neurol; 1974; 5():87-99. PubMed ID: 4155238 [No Abstract] [Full Text] [Related]
13. L-Dopa and the treatment of extrapyramidal disease. Pelton EW; Chase TN Adv Pharmacol Chemother; 1975; 13():253-304. PubMed ID: 1106161 [No Abstract] [Full Text] [Related]
14. Alpha-Monofluoromethyldopa (MFMD) in combination with L-DOPA Effects on tissue catecholamines and blood pressure in rats. Johansson P; Henning M Naunyn Schmiedebergs Arch Pharmacol; 1982 Oct; 321(1):28-31. PubMed ID: 7144925 [TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)]. Namba S; Ishimitsu H; Nakasone S No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908 [No Abstract] [Full Text] [Related]
16. [Pharmacology of several aromatic amino acid decarboxylase inhibitors]. Uspenskiĭ AE; Dabagov NS; Skoldinov AP Biull Eksp Biol Med; 1978 Oct; 86(10):444-7. PubMed ID: 309344 [TBL] [Abstract][Full Text] [Related]
17. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. Lindén IB; Nissinen E; Etemadzadeh E; Kaakkola S; Männistö P; Pohto P J Pharmacol Exp Ther; 1988 Oct; 247(1):289-93. PubMed ID: 3171977 [TBL] [Abstract][Full Text] [Related]